Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer

BACKGROUND: Metastatic colorectal cancers (MCRCs) with microsatellite stability (MSS) are resistant to immunotherapy with programmed cell death protein 1 (PD‐1) and programmed death‐ligand 1 inhibitors. However, the addition of regorafenib to nivolumab was recently associated with a high response ra...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Wang, Chongkai, Chevalier, Dawnyel, Saluja, Janelle, Sandhu, Jaideep, Lau, Cecilia, Fakih, Marwan
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons, Inc. 2020
Témata:
Gastrointestinal Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418365/
https://ncbi.nlm.nih.gov/pubmed/32406541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky